Subcutaneous Drug Delivery Devices Market Report 2024

This Subcutaneous Drug Delivery Devices market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The subcutaneous drug delivery devices market size has grown strongly in recent years. It will grow from $25.78 billion in 2023 to $27.66 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historic period can be attributed to the increasing prevalence of chronic diseases, a growing demand for self-administration of drugs, rising rates of diabetes and obesity, patient preference for convenient treatments, and the expanding geriatric population.

The subcutaneous drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $36.89 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth projected for the forecast period can be attributed to the expansion of the biologics and biosimilars market, increasing adoption of wearable drug delivery systems, the growth of personalized medicine, improvements in healthcare reimbursement policies, and a growing emphasis on home healthcare. Key trends expected include the integration of digital health technologies, the development of smart and connected devices, a rise in minimally invasive procedures, advancements in needle-free injection systems, and the emergence of artificial intelligence in device development.

The growing prevalence of diabetes and cardiovascular diseases (CVD) is expected to drive the expansion of the subcutaneous drug delivery devices market. The rise in these conditions is largely due to aging populations, poor diets, sedentary lifestyles, obesity, socioeconomic disparities, stress, environmental factors, and limited access to preventive healthcare. Subcutaneous drug delivery devices are widely used in diabetes management to administer insulin and other medications for glycemic control, as well as in CVD to deliver drugs like anticoagulants or lipid-lowering agents, offering a convenient and controlled way to manage these chronic diseases. For example, in April 2023, the British Diabetic Association, a UK-based charity, reported that 4.3 million people in the UK are currently living with diabetes, with new diagnoses increasing by 148,951 from 2020-21 to 2021-22. Additionally, over 2.4 million people in the UK are at high risk of developing type 2 diabetes. Furthermore, in May 2024, the Centers for Disease Control and Prevention (CDC) in the U.S. revealed that heart disease caused 702,880 deaths in 2022, accounting for 1 in every 5 deaths. As a result, the rising prevalence of diabetes and cardiovascular diseases is driving the growth of the subcutaneous drug delivery devices market.

Key players in the subcutaneous drug delivery device market are concentrating on developing advanced products such as miniature digital liquid flow sensors to improve the safety and accuracy of drug delivery. These sensors provide precise measurements of liquid flow rates and are especially useful for large-volume injectors. For instance, in May 2024, Sensirion AG, a Switzerland-based provider of environmental and flow sensors, introduced the SLD3x series sensor platform. This series includes highly accurate digital liquid flow sensors with customizable features, enabling precise flow measurement, occlusion detection, air bubble identification, and liquid temperature monitoring. These miniature sensors are suitable for large-scale medical device production, ensuring optimal dosing and enhanced patient safety in subcutaneous drug delivery.

In May 2022, Halozyme Therapeutics Inc., a US-based biopharmaceutical company, acquired Antares Pharma Inc. for $0.96 billion. This acquisition aims to enhance Halozyme's biopharmaceutical capabilities by incorporating Antares' innovative drug delivery technologies and expanding its portfolio. The goal is to improve patient outcomes and accelerate the global development of Halozyme’s ENHANZE technology. Antares Pharma Inc., also based in the US, specializes in subcutaneous drug delivery devices.

Major companies operating in the subcutaneous drug delivery devices market are Pfizer Inc., Sanofi S.A., Roche Holdings Inc., Medtronic plc, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Becton Dickinson and Company, West Pharmaceutical Services Inc., Gerresheimer AG, Insulet Corporation, SHL Medical AG, Tandem Diabetes Care Inc., Ypsomed Holding AG, Nemera, Elcam Medical Ltd., Owen Mumford Ltd., Haselmeier GmbH, Sensile Medical AG, Enable Injections Inc., Unilife Corporation, PharmaJet, Oval Medical Technologies Ltd.

North America was the largest region in the subcutaneous drug delivery devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the market going forward. The regions covered in the subcutaneous drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the subcutaneous drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Subcutaneous drug delivery devices are medical devices designed to administer medications directly into the subcutaneous tissue, which is the layer of fat and connective tissue just beneath the skin. These devices are employed for delivering various drugs, including insulin, hormones, and biologics, offering a convenient and minimally invasive method of administration.

The main types of subcutaneous drug delivery devices include insulin pens, pen needles, injector pens, auto-injectors, and implantable pumps. Insulin pens are handheld devices used for precise and convenient insulin administration in diabetes management, enabling users to easily measure and inject doses. These devices are used in various applications, such as diabetes, fertility, and oncology, and are utilized by different end-users, including hospitals, clinics, homecare settings, and ambulatory surgical centers.

The subcutaneous drug delivery devices market research report is one of a series of new reports that provides subcutaneous drug delivery devices market statistics, including subcutaneous drug delivery devices industry global market size, regional shares, competitors with a subcutaneous drug delivery devices market share, detailed subcutaneous drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the subcutaneous drug delivery devices industry. This subcutaneous drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The subcutaneous drug delivery devices market consists of sales of needles, cartridges, and reservoirs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.